<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>VIDAZA- azacitidineÂ injection, powder, lyophilized, for suspensionÂ </strong><br>Pharmion Corporation<br></p></div>
<h1>Vidazaâ„¢<br>(azacitidine for injectable suspension)</h1>
<div class="Contents">
<div class="Section">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="e1"></a><a name="section-2"></a><p></p>
<p class="First"><span class="Bold">Rx only</span></p>
<p>For subcutaneous use only</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s1"></a><a name="section-3"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Vidazaâ„¢ (azacitidine for injectable suspension) contains azacitidine, which is a pyrimidine nucleoside analog of cytidine. Azacitidine is 4-amino-1-Î²-D-ribofuranosyl-s-triazin-2(1<span class="Italics">H</span>)-one. The structural formula is as follows:</p>
<div class="Figure">
<a name="f1"></a><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e437efe0-9c6a-4f87-b3b4-de90443b095f&amp;name=vidaza-01.jpg">
</div>
<p>The empirical formula is C<span class="Sub">8</span>H<span class="Sub">12</span>N<span class="Sub">4</span>O<span class="Sub">5.</span>    The molecular weight is 244.  Azacitidine is a white to off-white solid. Azacitidine was found to be insoluble in acetone, ethanol, and methyl ethyl ketone; slightly soluble in ethanol/water (50/50), propylene glycol, and polyethylene glycol; sparingly soluble in water, water saturated octanol, 5% dextrose in water, N-methyl-2-pyrrolidone, normal saline and 5% Tween 80 in water; and soluble in dimethylsulfoxide (DMSO).</p>
<p>The finished product is supplied in a sterile form for reconstitution and subcutaneous injection only.  Vials of Vidaza contain 100 mg of azacitidine and 100 mg mannitol as a sterile lyophilized powder.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s2"></a><a name="section-4"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s3"></a><a name="section-4.1"></a><p></p>
<h2>Mechanism of Action</h2>
<p class="First">Vidaza is believed to exert its antineoplastic effects by causing hypomethylation of DNA and direct cytotoxicity on abnormal hematopoietic cells in the bone marrow.  The concentration of azacitidine required for maximum inhibition of DNA methylation <span class="Italics">in vitro</span> does not cause major suppression of DNA synthesis.  Hypomethylation may restore normal function to genes that are critical for differentiation and proliferation. The cytotoxic effects of azacitidine cause the <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> of rapidly dividing cells, including cancer cells that are no longer responsive to normal growth control mechanisms. Non-proliferating cells are relatively insensitive to Vidaza.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s4"></a><a name="section-4.2"></a><p></p>
<h2>Pharmacokinetics</h2>
<p class="First">The pharmacokinetics of azacitidine were studied in six MDS patients following a single 75 mg/m<span class="Sup">2</span> subcutaneous (SC) dose and a single 75 mg/m<span class="Sup">2</span> intravenous (IV) dose.  Azacitidine is rapidly absorbed after SC administration; the peak plasma azacitidine concentration of 750Â Â±Â 403 ng/ml occurred in 0.5 hour. The bioavailability of SC azacitidine relative to IV azacitidine is approximately 89%, based on area under the curve. Mean volume of distribution following IV dosing is 76 Â± 26 L.   Mean apparent SC clearance is 167 Â± 49 L/hour and mean half-life after SC administration is 41 Â± 8 minutes.</p>
<p>Published studies indicate that urinary excretion is the primary route of elimination of azacitidine and its metabolites.  Following IV administration of radioactive azacitidine to 5 cancer patients, the cumulative urinary excretion was 85% of the radioactive dose. Fecal excretion accounted for &lt;1% of administered radioactivity over three days.  Mean excretion of radioactivity in urine following SC administration of <span class="Sup">14</span>C-azacitidine was 50%.  The mean elimination half-lives of total radioactivity (azacitidine and its metabolites) were similar after IV and SC administrations, about 4 hours.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5"></a><a name="section-4.3"></a><p></p>
<h2>Special Populations</h2>
<p class="First">The effects of renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, gender, age, or race on the pharmacokinetics of azacitidine have not been studied (see <span class="Bold"><a href="#s9">CONTRAINDICATIONS, </a></span><span class="Bold"><a href="#s13">PRECAUTIONS</a></span> and <span class="Bold"><a href="#s50">DOSAGE AND ADMINISTRATION</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s6"></a><a name="section-4.4"></a><p></p>
<h2>Drug-Drug Interactions</h2>
<p class="First">Drug interaction studies with azacitidine have not been conducted.</p>
<p>An <span class="Italics">in vitro</span> study of azacitidine incubation in human liver fractions indicated that azacitidine may be metabolized by the liver. Whether azacitidine metabolism may be affected by known microsomal enzyme inhibitors or inducers has not been studied.</p>
<p>The potential of azacitidine to inhibit cytochrome P450 (CYP) enzymes is not known.</p>
<p><span class="Italics">In vitro</span> studies with human cultured hepatocytes indicate that azacitidine at concentrations of 1.0 Î¼M to 100 Î¼M does not induce CYP 1A2, 2C19, or 3A4/5.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="s7"></a><a name="section-5"></a><p></p>
<h1>CLINICAL STUDIES</h1>
<p class="First">A randomized, open-label, controlled trial carried out in 53 U.S. sites compared the safety and efficacy of subcutaneous Vidaza plus supportive care with supportive care alone (â€œobservationâ€?) in patients with any of the five FAB subtypes of <span class="product-label-link" type="condition" conceptid="138994" conceptname="Myelodysplastic syndrome">myelodysplastic syndromes</span> (MDS):  <span class="product-label-link" type="condition" conceptid="4003185" conceptname="Refractory anemia">refractory anemia</span> (RA), RA with ringed sideroblasts (RARS), RA with excess blasts (<span class="product-label-link" type="condition" conceptid="136949" conceptname="Refractory anemia with excess blasts">RAEB</span>), <span class="product-label-link" type="condition" conceptid="136949" conceptname="Refractory anemia with excess blasts">RAEB</span> in transformation (<span class="product-label-link" type="condition" conceptid="136949" conceptname="Refractory anemia with excess blasts">RAEB</span>-T), and <span class="product-label-link" type="condition" conceptid="136056" conceptname="Chronic monocytic leukemia">chronic myelomonocytic leukemia</span> (CMMoL).  RA and RARS patients were included if they met one or more of the following criteria:  required packed RBC transfusions; had platelet counts â‰¤ 50.0 x 10<span class="Sup">9</span>/L; required platelet transfusions; or were neutropenic (ANC &lt; 1.0 x 10<span class="Sup">9</span>/L) with <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> requiring treatment with antibiotics. Patients with acute myelogenous <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> (AML) were not intended to be included.  Baseline patient and disease characteristics are summarized in <a href="#t1">Table 1</a>; the 2 groups were similar.</p>
<p>Vidaza was administered at a subcutaneous dose of 75 mg/m<span class="Sup">2</span> daily for seven days every four weeks. The dose was increased to 100 mg/m<span class="Sup">2</span> if no beneficial effect was seen after two treatment cycles. The dose was decreased and/or delayed based on hematologic response or evidence of renal toxicity. Patients in the observation arm were allowed by protocol to cross over to Vidaza if they had increases in bone marrow blasts, decreases in hemoglobin, increases in red cell transfusion requirements, or decreases in platelets, or if they required a platelet transfusion or developed a clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> requiring treatment with antibiotics. For purposes of assessing efficacy, the primary endpoint was response rate (as defined in <a href="#t2">Table 2</a>).</p>
<p>Of the 191 patients included in the study, independent review (adjudicated diagnosis) found that 19 had the diagnosis of AML at baseline. These patients were excluded from the primary analysis of response rate, although they were included in an intent-to-treat (ITT) analysis of all patients randomized. Approximately 55% of the patients randomized to observation crossed over to receive Vidaza treatment.</p>
<a name="t1"></a><table rules="all">
<caption><span>Table 1.  Baseline Demographics and Disease Characteristics</span></caption>
<col align="left" width="52.167%">
<col align="left" width="23.133%">
<col align="left" width="24.700%">
<thead><tr class="First Last">
<th class="Lrule Rrule Toprule" align="left" valign="bottom"></th>
<th class="Lrule Rrule Toprule" align="center" valign="bottom">Vidaza<br>(N=99)</th>
<th class="Lrule Rrule Toprule" align="center" valign="bottom">Observation<br>(N=92)</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Gender (n%)</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="top"></td>
<td class="Lrule Rrule Toprule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top">Male</td>
<td class="Lrule Rrule Toprule" align="center" valign="top"> 72 (72.7)</td>
<td class="Lrule Rrule Toprule" align="center" valign="top"> 60 (65.2)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top">Female</td>
<td class="Lrule Rrule Toprule" align="center" valign="top"> 27 (27.3)</td>
<td class="Lrule Rrule Toprule" align="center" valign="top"> 32 (34.8)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="Bold">Race (n%)</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="top"></td>
<td class="Lrule Rrule Toprule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top">White</td>
<td class="Lrule Rrule Toprule" align="center" valign="top"> 93 (93.9)</td>
<td class="Lrule Rrule Toprule" align="center" valign="top"> 85 (92.4)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top">Black</td>
<td class="Lrule Rrule Toprule" align="center" valign="top"> 1 (1.0)</td>
<td class="Lrule Rrule Toprule" align="center" valign="top"> 1 (1.1)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top">Hispanic</td>
<td class="Lrule Rrule Toprule" align="center" valign="top"> 3 (3.0)</td>
<td class="Lrule Rrule Toprule" align="center" valign="top"> 5 (5.4)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top">Asian/Oriental</td>
<td class="Lrule Rrule Toprule" align="center" valign="top"> 2 (2.0)</td>
<td class="Lrule Rrule Toprule" align="center" valign="top"> 1 (1.1)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Age (years)</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="top"></td>
<td class="Lrule Rrule Toprule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top">N</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">99</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">91</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top">Mean Â± SD</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">67.3 Â± 10.39</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">68.0 Â± 10.23</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top">Range</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">31 - 92</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">35 - 88</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Adjudicated MDS diagnosis at study entry (n%)</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="top"></td>
<td class="Lrule Rrule Toprule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top">RA</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">21 (21.2)</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">18 (19.6)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top">RARS</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">6 (6.1)</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">5 (5.4)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="136949" conceptname="Refractory anemia with excess blasts">RAEB</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="top">38 (38.4)</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">39 (42.4)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="136949" conceptname="Refractory anemia with excess blasts">RAEB</span>-T</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">16 (16.2)</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">14 (15.2)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top">CMMoL</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">8 (8.1)</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">7 (7.6)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top">AML</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">10 (10.1)</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">9 (9.8)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Transfusion product used in 3 months before study entry (n%)</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="top"></td>
<td class="Lrule Rrule Toprule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top">Any transfusion product</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">70 (70.7)</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">59 (64.1)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top">Blood cells, packed human</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">66 (66.7)</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">55 (59.8)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top">Platelets, human blood</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">15 (15.2)</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">12 (13.0)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top">Hetastarch</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">0(0.0)</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">1(1.1)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top">Plasma protein fraction</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">1(1.0)</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">0(0.0)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule Toprule" align="left" valign="top">Other</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">2(2.0)</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">2(2.2)</td>
</tr>
</tbody>
</table>
<a name="t2"></a><table rules="all">
<caption><span>Table 2.  Response Criteria</span></caption>
<col align="left" width="16.100%">
<col align="left" width="15.171%">
<col align="left" width="12.800%">
<col align="left" width="13.429%">
<col align="left" width="13.400%">
<col align="left" width="15.329%">
<col align="left" width="13.771%">
<thead><tr class="First Last">
<th class="Lrule Rrule Toprule" align="left" colspan="2" valign="top"></th>
<th class="Lrule Rrule Toprule" align="center" valign="middle"><span class="Bold">RA</span></th>
<th class="Lrule Rrule Toprule" align="center" valign="middle"><span class="Bold">RARS</span></th>
<th class="Lrule Rrule Toprule" align="center" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="136949" conceptname="Refractory anemia with excess blasts">RAEB</span></span></th>
<th class="Lrule Rrule Toprule" align="center" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="136949" conceptname="Refractory anemia with excess blasts">RAEB</span>-T</span></th>
<th class="Lrule Rrule Toprule" align="center" valign="middle"><span class="Bold">CMMoL</span></th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Lrule Rrule Toprule" align="left" rowspan="2" valign="middle">
<span class="Bold">Complete</span><br><span class="Bold">Response</span><br><span class="Bold">(CR),</span> duration â‰¥ 4 weeks</td>
<td class="Lrule Rrule Toprule" align="left" valign="middle"><span class="Bold">Marrow</span></td>
<td class="Lrule Rrule Toprule" align="left" colspan="5" valign="middle">&lt; 5% blasts</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="middle">
<span class="Bold">Peripheral</span><br><span class="Bold">Blood</span>
</td>
<td class="Lrule Rrule Toprule" align="left" colspan="5" valign="top">Normal CBC if abnormal at baseline<br>Absence of blasts in the peripheral circulation</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" rowspan="2" valign="top">
<span class="Bold">Partial</span><br><span class="Bold">Response</span><br><span class="Bold">(PR),</span> duration â‰¥ 4 weeks</td>
<td class="Lrule Rrule Toprule" align="left" valign="middle"><span class="Bold">Marrow</span></td>
<td class="Lrule Rrule Toprule" align="left" colspan="2" valign="middle">No marrow requirements<br>
</td>
<td class="Lrule Rrule Toprule" align="left" colspan="3" valign="middle">â‰¥50% decrease in blasts<br>Improvement of marrow dyspoiesis</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule Toprule" align="left" valign="top">
<br><span class="Bold">Peripheral</span><br><span class="Bold">Blood</span>
</td>
<td class="Lrule Rrule Toprule" align="left" colspan="5" valign="top">â‰¥50% restoration in the deficit from normal levels of baseline white cells, hemoglobin and platelets if abnormal at baseline<br><br>No blasts in the peripheral circulation<br><br>For CMMoL, if WBC is elevated at baseline, a â‰¥ 75% reduction in the excess count over the upper limit of normal<br>
</td>
</tr>
</tbody>
</table>
<p>The overall response rate (CR +PR) of 15.7% in Vidaza-treated patients without AML (16.2%Â for all Vidaza randomized patients including AML) was statistically significantly higher than the response rate of 0% in the observation group (p&lt;0.0001) (<a href="#t3">Table 3</a>).  The majority of patients who achieved either CR or PR had either 2 or 3 cell line abnormalities at baseline (79%; 11/14) and had elevated bone marrow blasts or were transfusion dependent at baseline. Patients responding to Vidaza had a decrease in bone marrow blasts percentage, or an increase in platelets, hemoglobin or WBC.  Greater than 90% of the responders initially demonstrated these changes by the 5th treatment cycle. All patients who had been transfusion dependent became transfusion independent during PR or CR.  The mean and median duration of clinical response of PR or better was estimated as 512 and 330 days, respectively; 75% of the responding patients were still in PR or better at completion of treatment. Response occurred in all MDS subtypes as well as in patients with adjudicated baseline diagnosis of AML.</p>
<a name="t3"></a><table rules="all">
<caption><span>Table 3.  Response Rates</span></caption>
<col align="left" width="30.975%">
<col align="left" width="18.525%">
<col align="left" width="32.650%">
<col align="left" width="17.850%">
<thead>
<tr class="First">
<th class="Lrule Rrule Toprule" align="left" valign="top"></th>
<th class="Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">Vidaza<br>(N=89)</span></th>
<th class="Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">Observation Before Crossover<br>(N=83)</span></th>
<th class="Lrule Rrule Toprule" align="center" valign="top"></th>
</tr>
<tr class="Last">
<th class="Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Response</span></th>
<th class="Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">nÂ (%)</span></th>
<th class="Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">NÂ (%)</span></th>
<th class="Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">P value</span></th>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="Lrule Rrule Toprule" align="left" valign="top">Overall (CR+PR)</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">14 (15.7)</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">0 ( 0.0)</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">(&lt;0.0001)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top">Â Â Â Complete (CR)</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">5 ( 5.6)</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">0 ( 0.0)</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">(0.06)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule Toprule" align="left" valign="top">Â Â Â Partial (PR)</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">9 (10.1)</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">0 ( 0.0)</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">--</td>
</tr>
</tbody>
</table>
<p>Patients in the observation group who crossed over to receive Vidaza treatment (47 patients) had a response rate of 12.8%.</p>
<p>A multi-center, open-label, single-arm study of 72 patients with <span class="product-label-link" type="condition" conceptid="136949" conceptname="Refractory anemia with excess blasts">RAEB</span>, <span class="product-label-link" type="condition" conceptid="136949" conceptname="Refractory anemia with excess blasts">RAEB</span>-T, CMMoL, or AML was also carried out.  Treatment with subcutaneous Vidaza resulted in a response rate (CR + PR) of 13.9%, using criteria similar to those described above.  The mean and median duration of clinical response of PR or better was estimated as 810 and 430 days, respectively; 80% of the responding patients were still in PR or better at the time of completion of study involvement.   In another open-label, single-arm study of 48 patients with <span class="product-label-link" type="condition" conceptid="136949" conceptname="Refractory anemia with excess blasts">RAEB</span>, <span class="product-label-link" type="condition" conceptid="136949" conceptname="Refractory anemia with excess blasts">RAEB</span>-T, or AML, treatment with intravenous Vidaza resulted in a response rate of 18.8%, again using criteria similar to those described above.  The mean and median duration of clinical response of PR or better was estimated as 389 and 281 days, respectively; 67% of the responding patients were still in PR or better at the time of completion of treatment.  Response occurred in all MDS subtypes as well as in patients with adjudicated baseline diagnosis of AML in both of these studies. Vidaza dosage regimens in these 2 studies were similar to the regimen used in the controlled study.</p>
<p>Benefit was seen in patients who did not meet the criteria for PR or better, but were considered â€œimproved.â€?  About 24% of Vidaza-treated patients were considered improved, and about 2/3 of those lost transfusion <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>. In the observation group, only 5/83 patients met criteria for improvement; none lost transfusion <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>.  In all three studies, about 19% of patients met criteria for improvement with a median duration of 195 days.</p>
<p>Response rate estimates were similar regardless of age or gender.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s8"></a><a name="section-6"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Vidaza is indicated for treatment of patients with the following <span class="product-label-link" type="condition" conceptid="138994" conceptname="Myelodysplastic syndrome">myelodysplastic syndrome</span> subtypes:  <span class="product-label-link" type="condition" conceptid="4003185" conceptname="Refractory anemia">refractory anemia</span> or <span class="product-label-link" type="condition" conceptid="4003185" conceptname="Refractory anemia">refractory anemia</span> with ringed sideroblasts (if accompanied by <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> or <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> or requiring transfusions), <span class="product-label-link" type="condition" conceptid="4003185" conceptname="Refractory anemia">refractory anemia</span> with excess blasts, <span class="product-label-link" type="condition" conceptid="4003185" conceptname="Refractory anemia">refractory anemia</span> with excess blasts in transformation, and <span class="product-label-link" type="condition" conceptid="136056" conceptname="Chronic monocytic leukemia">chronic myelomonocytic leukemia</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s9"></a><a name="section-7"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Vidaza is contraindicated in patients with a known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to azacitidine or mannitol.  Vidaza is also contraindicated in patients with advanced malignant hepatic tumors.  (See <span class="Bold"><a href="#s13">PRECAUTIONS</a></span>).</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="s10"></a><a name="section-8"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s11"></a><a name="section-8.1"></a><p></p>
<h2>Pregnancy - Teratogenic Effects:  Pregnancy Category D</h2>
<p class="First">Vidaza may cause fetal harm when administered to a pregnant woman. Early embryotoxicity studies in mice revealed a 44% frequency of intrauterine embryonal <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> (increased resorption) after a single IP (intraperitoneal) injection of 6 mg/m<span class="Sup">2</span> (approximately 8% of the recommended human daily dose on a mg/m<span class="Sup">2</span> basis) azacitidine on gestation day 10. Developmental abnormalities in the brain have been detected in mice given azacitidine on or before gestation day 15 at doses of ~3-12Â mg/m<span class="Sup">2</span> (approximately 4%-16% the recommended human daily dose on a mg/m<span class="Sup">2</span> basis).</p>
<p>In rats, azacitidine was clearly embryotoxic when given IP on gestation days 4-8 (postimplantation) at a dose of 6Â mg/m<span class="Sup">2</span> (approximately 8% of the recommended human daily dose on a mg/m<span class="Sup">2</span> basis), although treatment in the preimplantation period (on gestation days 1-3) had no adverse effect on the embryos.  Azacitidine caused multiple fetal abnormalities in rats after a single IP dose of 3 to 12Â mg/m<span class="Sup">2</span> (approximately 8% the recommended human daily dose on a mg/m<span class="Sup">2</span> basis) given on gestation day 9, 10, 11 or 12. In this study azacitidine caused <span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">fetal death</span> when administered at 3-12 mg/m<span class="Sup">2</span> on gestation days 9 and 10; average live animals per litter was reduced to 9% of control at the highest dose on gestation day 9.  Fetal anomalies included: CNS anomalies (<span class="product-label-link" type="condition" conceptid="4309376" conceptname="Exencephaly">exencephaly</span>/<span class="product-label-link" type="condition" conceptid="432419" conceptname="Encephalocele">encephalocele</span>), limb anomalies (<span class="product-label-link" type="condition" conceptid="73307" conceptname="Transverse deficiency of lower limb">micromelia</span>, club foot, <span class="product-label-link" type="condition" conceptid="4162283" conceptname="Syndactyly">syndactyly</span>, oligodactyly), and others (<span class="product-label-link" type="condition" conceptid="4140216" conceptname="Congenital micrognathism">micrognathia</span>, <span class="product-label-link" type="condition" conceptid="4218764" conceptname="Gastroschisis">gastroschisis</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, and rib abnormalities).</p>
<p>There are no adequate and well-controlled studies in pregnant women using Vidaza.  If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.</p>
<p>Women of childbearing potential should be advised to avoid becoming pregnant while receiving treatment with Vidaza.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s12"></a><a name="section-8.2"></a><p></p>
<h2>Use in Males</h2>
<p class="First">Men should be advised to not father a child while receiving treatment with Vidaza. (See <span class="Bold"><a href="#s18">PRECAUTIONS: Carcinogenesis, Mutagenesis, Impairment of Fertility</a></span> for discussion of pre-mating effects of azacitidine exposure on male fertility and embryonic viability.)</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="s13"></a><a name="section-9"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="s14"></a><a name="section-9.1"></a><p></p>
<h2>General</h2>
<p class="First">Treatment with Vidaza is associated with <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>. Complete blood counts should be performed as needed to monitor response and toxicity, but at a minimum, prior to each dosing cycle.  After administration of the recommended dosage for the first cycle, dosage for subsequent cycles should be reduced or delayed based on nadir counts and hematologic response as described in <span class="Bold"><a href="#s50">DOSAGE AND ADMINISTRATION</a></span>.</p>
<p>Safety and effectiveness of Vidaza in patients with MDS and hepatic or <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> have not been studied as these patients were excluded from the clinical trials.</p>
<p>Because azacitidine is potentially hepatotoxic in patients with severe pre-existing <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, caution is needed in patients with liver disease. Patients with extensive tumor burden due to <span class="product-label-link" type="condition" conceptid="4116496" conceptname="Disseminated adenocarcinoma">metastatic disease</span> have been rarely reported to experience progressive <span class="product-label-link" type="condition" conceptid="377604" conceptname="Hepatic coma">hepatic coma</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> during azacitidine treatment, especially in such patients with baseline albumin &lt;30 g/L.  Azacitidine is contraindicated in patients with advanced malignant hepatic tumors (See <span class="Bold"><a href="#s9">CONTRAINDICATIONS</a></span>).</p>
<p>Renal abnormalities ranging from elevated serum creatinine to <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> have been reported rarely in patients treated with intravenous azacitidine in combination with other chemotherapeutic agents for non-MDS conditions. In addition, <span class="product-label-link" type="condition" conceptid="4070448" conceptname="Renal tubular acidosis">renal tubular acidosis</span>, defined as a <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> in serum <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> to &lt;20Â mEq/L in association with an alkaline urine and <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> (serum potassium &lt;3Â mEq/L) developed in 5 patients with CML treated with azacitidine and etoposide. If unexplained reductions in serum <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> &lt;20 mEq/L or elevations of BUN or serum creatinine occur, the dosage should be reduced or held as described in <span class="Bold"><a href="#s50">DOSAGE AND ADMINISTRATION</a></span></p>
<p>Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> should be closely monitored for toxicity since azacitidine and its metabolites are primarily excreted by the kidneys (see <span class="Bold"><a href="#s50">DOSAGE AND ADMINISTRATION</a></span> section).</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s15"></a><a name="section-9.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Patients should inform their physician about any underlying liver or <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>.</p>
<p>Women of childbearing potential should be advised to avoid becoming pregnant while receiving treatment with Vidaza.</p>
<p>Men should be advised to not father a child while receiving treatment with Vidaza.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="s16"></a><a name="section-9.3"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">Complete blood counts should be performed as needed to monitor response and toxicity, but at a minimum, prior to each cycle.  Liver chemistries and serum creatinine should be obtained prior to initiation of therapy.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s17"></a><a name="section-9.4"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">No formal assessments of drug-drug interactions between Vidaza and other agents have been conducted.  (See <span class="Bold"><a href="#s2">CLINICAL PHARMACOLOGY.</a></span>)</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="s18"></a><a name="section-9.5"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">The potential carcinogenicity of azacitidine was evaluated in mice and rats. Azacitidine induced tumors of the hematopoietic system in female mice at 2.2 mg/kg (6.6 mg/m<span class="Sup">2</span>, approximately 8% the recommended human daily dose on a mg/m<span class="Sup">2</span> basis) administered IP three times per week for 52 weeks. An increased incidence of tumors in the lymphoreticular system, lung, mammary gland, and skin was seen in mice treated with azacitidine IP at 2.0Â mg/kg (6.0Â mg/m<span class="Sup">2</span>, approximately 8% the recommended human daily dose on a mg/m<span class="Sup">2</span> basis) once a week for 50 weeks. A tumorigenicity study in rats dosed twice weekly at 15 or 60Â mg/m<span class="Sup">2</span> (approximately 20-80% the recommended human daily dose on a mg/m<span class="Sup">2</span> basis) revealed an increased incidence of testicular tumors compared with controls.</p>
<p>The mutagenic and clastogenic potential of azacitidine was tested in <span class="Italics">in vitro </span>bacterial systems<span class="Italics"> <span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> typhimurium </span><span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> TA100 and several <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of<span class="Italics"> trpE8, Escherichia coli</span>  <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> WP14 Pro, WP3103P, WP3104P, and CC103; in<span class="Italics"> in vitro </span>forward gene mutation assay in mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> cells and human lymphoblast cells; and in an<span class="Italics"> in vitro </span>micronucleus assay in mouse L5178Y <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> cells and Syrian hamster embryo cells.  Azacitidine was mutagenic in bacterial and mammalian cell systems.  The clastogenic effect of azacitidine was shown by the induction of micronuclei in L5178Y mouse cells and Syrian hamster embryo cells.</p>
<p>Administration of azacitidine to male mice at 9.9 mg/m<span class="Sup">2</span> (approximately 9% the recommended human daily dose on a mg/m<span class="Sup">2</span> basis) daily for 3 days prior to mating with untreated female mice resulted in decreased fertility and loss of offspring during subsequent embryonic and postnatal development.  Treatment of male rats three times per week for 11 or 16 weeks at doses of 15 to 30 mg/m<span class="Sup">2</span> (approximately 20-40%, the recommended human daily dose on a mg/m<span class="Sup">2</span> basis) resulted in decreased weight of the testes and epididymides, and decreased sperm counts accompanied by decreased pregnancy rates and increased loss of embryos in mated females.  In a related study, male rats treated for 16 weeks at 24 mg/m<span class="Sup">2</span> resulted in an increase in abnormal embryos in mated females when examined on day 2 of gestation.  SeeÂ <span class="Bold"><a href="#s10">WARNINGS</a></span>. </p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="s19"></a><a name="section-9.6"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="s20"></a><a name="section-9.6.1"></a><p></p>
<h3>Teratogenic Effects:  Pregnancy Category D.  See WARNINGS section.</h3>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s21"></a><a name="section-9.7"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether azacitidine or its metabolites are excreted in human milk.  Because of the potential for tumorigenicity shown for azacitidine in animal studies and the potential for serious adverse reactions, women treated with azacitidine should not nurse.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s22"></a><a name="section-9.8"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s23"></a><a name="section-9.9"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Of the total number of patients in the three clinical studies described in <span class="Bold"><a href="#s7">CLINICAL STUDIES</a></span>, above, 62 percent were 65 years and older and  21 percent were 75 years and older.  No overall differences in effectiveness were observed between these patients and younger patients. In addition there were no relevant differences in the frequency of adverse events observed in patients 65 years and older compared to younger patients.</p>
<p>Azacitidine and its metabolites are known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>.  Because elderly patients are more likely to have decreased renal function, it may be useful to monitor renal function (see<span class="Bold"><a href="#s50">DOSAGE AND ADMINISTRATION</a></span> section).</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s24"></a><a name="section-10"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s25"></a><a name="section-10.1"></a><p></p>
<h2>Overview</h2>
<p class="First"><span class="Bold">Adverse Reactions Described in Other Labeling Sections:</span>  <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, elevated serum creatinine, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, <span class="product-label-link" type="condition" conceptid="4070448" conceptname="Renal tubular acidosis">renal tubular acidosis</span>, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="377604" conceptname="Hepatic coma">hepatic coma</span>.</p>
<p><span class="Bold">Most Commonly Occurring Adverse Reactions (SC Route):</span> <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, injection site <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymosis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s28"></a><a name="section-10.2"></a><p></p>
<h2>Adverse Reactions Most Frequently (&gt;2%) Resulting in Clinical Intervention (SC Route):</h2>
<p class="First"><span class="Underline">Discontinuation</span>: <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> (5.0%), <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> (3.6%), <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (2.7%).</p>
<p><span class="Underline">Dose Held</span>: <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> (4.5%), <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (4.5%), <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">febrile neutropenia</span> (2.7%).</p>
<p><span class="Underline">Dose Reduced</span>: <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> (4.5%), <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (4.1%), <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> (3.2%).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s32"></a><a name="section-10.3"></a><p></p>
<h2>Discussion of Adverse Reactions Information</h2>
<p class="First">The data described below reflect exposure to Vidaza in 268 patients, including 116 exposed for 6 cycles (approximately 6 months) or more and 60 exposed for greater than 12 cycles (approximately one year). Vidaza was studied primarily in supportive care-controlled and uncontrolled trials (n= 150 and n=118, respectively).  The population in the subcutaneous studies (n = 220) was 23 to 92 years old (mean 66.4 years), 68% male, and 94% white, and had MDS or AML. The population in the IV study (n = 48) was 35 to 81 years old (mean 63.1 years), 65% male, and 100% white. Most patients received average daily doses between 50 and 100 mg/m<span class="Sup">2</span>.</p>
<p>The following table presents the most common adverse events, whether or not considered drug related by investigators, occurring in at least 5% of patients treated with Vidaza in the supportive care-controlled trial and the uncontrolled subcutaneous trial combined. It is important to note that duration of exposure was longer for the Vidaza-treated group than for the observation group: patients received Vidaza for a mean of 11.4 months while mean time in the observation arm was 6.1 months.</p>
<a name="t4"></a><table rules="all">
<caption><span>Table 4:  Most Frequently Observed  Adverse Events (â‰¥Â 5% in All Vidaza)*</span></caption>
<col align="left" width="51.350%">
<col align="left" width="24.325%">
<col align="left" width="24.325%">
<thead>
<tr class="First">
<th class="Lrule Rrule Toprule" align="center" valign="bottom">Preferred Term**</th>
<th class="Lrule Rrule Toprule" align="center" valign="bottom">All Vidazaâ€¡<br>(N=220)</th>
<th class="Lrule Rrule Toprule" align="center" valign="bottom">Observationâ€ <br>(N=92)</th>
</tr>
<tr>
<th class="Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">At least 1 TEAE</span></th>
<th class="Lrule Rrule Toprule" align="center" valign="top"> 219 (99.5)</th>
<th class="Lrule Rrule Toprule" align="center" valign="top"> 89 (96.7)</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule Toprule" align="left" valign="top"></th>
<th class="Lrule Rrule Toprule" align="center" valign="top"></th>
<th class="Lrule Rrule Toprule" align="center" valign="top"></th>
</tr>
</thead>
<tfoot>
<tr class="First"><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Sup">*</span> Mean Vidaza exposure = 11.4 months. Mean time in observation arm = 6.1 months.</p></td></tr>
<tr><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Sup">**</span>Multiple reports of the same preferred terms for a patient are only counted once within each treatment group.</p></td></tr>
<tr><td align="left" colspan="3" valign="top"><p class="First Footnote">â€  Includes events from observation period only; excludes any events after crossover to Vidaza.</p></td></tr>
<tr class="Last"><td align="left" colspan="3" valign="top"><p class="First Footnote">â€¡ Includes events from all patients exposed to Vidaza, including patients after crossing over from observation.</p></td></tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Lrule Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="top"> 155 (70.5)</td>
<td class="Lrule Rrule Toprule" align="center" valign="top"> 16 (17.4)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="top"> 153 (69.5)</td>
<td class="Lrule Rrule Toprule" align="center" valign="top"> 59 (64.1)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="top"> 144 (65.5)</td>
<td class="Lrule Rrule Toprule" align="center" valign="top"> 42 (45.7)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="top"> 119 (54.1)</td>
<td class="Lrule Rrule Toprule" align="center" valign="top"> 5 (5.4)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="top"> 114 (51.8)</td>
<td class="Lrule Rrule Toprule" align="center" valign="top"> 28 (30.4)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="top"> 106 (48.2)</td>
<td class="Lrule Rrule Toprule" align="center" valign="top"> 27 (29.3)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="top"> 80 (36.4)</td>
<td class="Lrule Rrule Toprule" align="center" valign="top"> 13 (14.1)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="top"> 79 (35.9)</td>
<td class="Lrule Rrule Toprule" align="center" valign="top"> 23 (25.0)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top">Injection site <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="top"> 77 (35.0)</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">0</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="top"> 74 (33.6)</td>
<td class="Lrule Rrule Toprule" align="center" valign="top"> 6 (6.5)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="top"> 71 (32.3)</td>
<td class="Lrule Rrule Toprule" align="center" valign="top"> 10 (10.9)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">Ecchymosis</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="top"> 67 (30.5)</td>
<td class="Lrule Rrule Toprule" align="center" valign="top"> 14 (15.2)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="top"> 65 (29.5)</td>
<td class="Lrule Rrule Toprule" align="center" valign="top"> 14 (15.2)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="top"> 64 (29.1)</td>
<td class="Lrule Rrule Toprule" align="center" valign="top"> 11 (12.0)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Weakness</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="top"> 64 (29.1)</td>
<td class="Lrule Rrule Toprule" align="center" valign="top"> 19 (20.7)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Rigors</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="top"> 56 (25.5)</td>
<td class="Lrule Rrule Toprule" align="center" valign="top"> 10 (10.9)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">Petechiae</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="top"> 52 (23.6)</td>
<td class="Lrule Rrule Toprule" align="center" valign="top"> 8 (8.7)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4316207" conceptname="Injection site pain">Injection site pain</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="top"> 50 (22.7)</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">0</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="top"> 49 (22.3)</td>
<td class="Lrule Rrule Toprule" align="center" valign="top"> 3 (3.3)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="top"> 48 (21.8)</td>
<td class="Lrule Rrule Toprule" align="center" valign="top"> 10 (10.9)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="top"> 45 (20.5)</td>
<td class="Lrule Rrule Toprule" align="center" valign="top"> 6 (6.5)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">Pain in limb</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="top"> 44 (20.0)</td>
<td class="Lrule Rrule Toprule" align="center" valign="top"> 5 (5.4)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="top"> 44 (20.0)</td>
<td class="Lrule Rrule Toprule" align="center" valign="top"> 7 (7.6)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 41 (18.6)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 7 (7.6)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">Contusion</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 41 (18.6)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 9 (9.8)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 41 (18.6)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 5 (5.4)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Edema peripheral</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 41 (18.6)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 10 (10.9)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">Erythema</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 37 (16.8)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 4 (4.3)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 36 (16.4)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 5 (5.4)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">Epistaxis</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 36 (16.4)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 9 (9.8)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">Febrile neutropenia</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 36 (16.4)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 4 (4.3)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 35 (15.9)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 2 (2.2)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">Weight decreased</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 35 (15.9)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 10 (10.9)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span> </td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 34 (15.5)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 12 (13.0)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">Pallor</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 34 (15.5)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 7 (7.6)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">Nasopharyngitis</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 32 (14.5)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 3 (3.3)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Pitting edema</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 32 (14.5)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 9 (9.8)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="4316083" conceptname="Skin lesion">Skin lesion</span> </td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 32 (14.5)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 8 (8.7)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="4263848" conceptname="Dyspnea on exertion">Dyspnea exertional</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 31 (14.1)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 15 (16.3)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="4317277" conceptname="Injection site bruising">Injection site bruising</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 31 (14.1)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 0</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> </td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 31 (14.1)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 9 (9.8)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">Injection site reaction</span> </td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 30 (13.6)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 0</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 29 (13.2)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 3 (3.3)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Appetite decreased</span> </td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 28 (12.7)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 8 (8.7)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue aggravated</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 28 (12.7)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 4 (4.3)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 28 (12.7)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 12 (13.0)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory tract infection</span> </td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 28 (12.7)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 4 (4.3)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span> </td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 27 (12.3)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 11 (12.0)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="197981" conceptname="Abdominal tenderness">Abdominal tenderness</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 26 (11.8)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 1 (1.1)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 26 (11.8)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 7 (7.6)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">Productive cough</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 25 (11.4)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 4 (4.3)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 24 (10.9)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 4 (4.3)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">Malaise</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 24 (10.9)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 1 (1.1)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> </td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 24 (10.9)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 3 (3.3)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span> </td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 24 (10.9)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 5 (5.4)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">Abdominal pain upper</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 23 (10.5)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 3 (3.3)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="4167669" conceptname="Respiratory crackles">Crackles lung</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 23 (10.5)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 8 (8.7)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Sweating increased</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 23 (10.5)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 2 (2.2)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="316822" conceptname="Heart murmur">Cardiac murmur</span> </td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 22 (10.0)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 8 (8.7)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">Rhinorrhea</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 22 (10.0)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 2 (2.2)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="4311406" conceptname="Bleeding gums">Gingival bleeding</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 21 (9.5)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 4 (4.3)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">Lymphadenopathy</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 21 (9.5)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 3 (3.3)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom">Herpes simplex</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 20 (9.1)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 5 (5.4)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">Hematoma</span> </td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 19 (8.6)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 0</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="4181178" conceptname="Night sweats">Night sweats</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 19 (8.6)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 3 (3.3)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="4167669" conceptname="Respiratory crackles">Rales</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 19 (8.6)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 8 (8.7)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span> </td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 19 (8.6)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 6 (6.5)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">Wheezing</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 19 (8.6)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 2 (2.2)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="435613" conceptname="Cellulitis">Cellulitis</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 18 (8.2)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 4 (4.3)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">Dysuria</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 18 (8.2)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 2 (2.2)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="73026" conceptname="Abnormal breath sounds">Breath sounds decreased</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 17 (7.7)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 1 (1.1)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">Lethargy</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 17 (7.7)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 2 (2.2)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="4330466" conceptname="Bleeding from mouth">Oral mucosal petechiae</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 17 (7.7)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 3 (3.3)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 17 (7.7)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 0</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infection</span> </td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 17 (7.7)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 5 (5.4)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="133299" conceptname="Swelling of limb">Peripheral swelling</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 16 (7.3)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 5 (5.4)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 15 (6.8)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 4 (4.3)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="194382" conceptname="External hemorrhoids">Hemorrhoids</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 15 (6.8)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 1 (1.1)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> </td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 15 (6.8)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 2 (2.2)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom">Injection site <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 15 (6.8)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 0</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="440603" conceptname="Blood transfusion reaction">Transfusion reaction</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 15 (6.8)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 0</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">Pleural effusion</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 14 (6.4)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 6 (6.5)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">Abdominal distension</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 13 (5.9)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 4 (4.3)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Muscle cramps</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 13 (5.9)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 3 (3.3)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="4002836" conceptname="Postoperative hemorrhage">Post procedural hemorrhage</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 13 (5.9)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 1 (1.1)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="257683" conceptname="Posterior rhinorrhea">Postnasal drip</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 13 (5.9)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 3 (3.3)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="4084392" conceptname="Wheeze - rhonchi">Rhonchi</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 13 (5.9)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 2 (2.2)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 13 (5.9)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 5 (5.4)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Urticaria</span> </td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 13 (5.9)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 1 (1.1)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia aggravated</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom">12   (5.5)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom">5   (5.4)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Loose stools</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 12 (5.5)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 0</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">Nasal congestion</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 12 (5.5)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 1 (1.1)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="261880" conceptname="Atelectasis">Atelectasis</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 11 (5.0)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 2 (2.2)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="4010016" conceptname="Chest wall pain">Chest wall pain</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 11 (5.0)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 0</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">Dry skin</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 11 (5.0)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 1 (1.1)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">Dysphagia</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 11 (5.0)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 2 (2.2)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea exacerbated</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 11 (5.0)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 3 (3.3)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">Hypoesthesia</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 11 (5.0)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 1 (1.1)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="4088038" conceptname="Injection site granuloma">Injection site granuloma</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 11 (5.0)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 0</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom">Injection site <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span> changes</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 11 (5.0)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 0</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="4319319" conceptname="Injection site edema">Injection site swelling</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 11 (5.0)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 0</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="4330466" conceptname="Bleeding from mouth">Mouth hemorrhage</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 11 (5.0)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 1 (1.1)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="439502" conceptname="Postoperative pain">Post procedural pain</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 11 (5.0)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 2 (2.2)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span> </td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 11 (5.0)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 3 (3.3)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="4042856" conceptname="Fibrous nodule">Skin nodule</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 11 (5.0)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 1 (1.1)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule Toprule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="4278836" conceptname="Ulcer on tongue">Tongue ulceration</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 11 (5.0)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> 2 (2.2)</td>
</tr>
</tbody>
</table>
<p><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, and <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> all tended to increase in incidence with increasing doses of Vidaza. <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, injection site <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">rigors</span>, <span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">petechiae</span>, <span class="product-label-link" type="condition" conceptid="4316207" conceptname="Injection site pain">injection site pain</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4317277" conceptname="Injection site bruising">injection site bruising</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>, and <span class="product-label-link" type="condition" conceptid="4167669" conceptname="Respiratory crackles">rales</span> tended to be more pronounced during the first 1-2Â cycles of SC Vidaza treatment compared with later cycles of treatment. There did not appear to be any adverse events that increased in frequency over the course of treatment. There did not appear to be any relevant differences in adverse events by gender.</p>
<p>In clinical studies of either SC or IV Vidaza, the following serious treatment-related adverse events occurring at a rate of &lt;5% (not described in <a href="#t4">Table 4</a>) were reported:</p>
<p><span class="Bold">Blood and lymphatic system disorders:</span>  <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">bone marrow depression</span>, <span class="product-label-link" type="condition" conceptid="200527" conceptname="Splenomegaly">splenomegaly</span>.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac disorders</span>:</span>  <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">cardiac failure congestive</span>, cardio-<span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span>, <span class="product-label-link" type="condition" conceptid="4163710" conceptname="Dilated cardiomyopathy">congestive cardiomyopathy</span>.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span>:</span>  <span class="product-label-link" type="condition" conceptid="4109737" conceptname="Diverticulitis">diverticulitis</span>, <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span>, <span class="product-label-link" type="condition" conceptid="4241157" conceptname="Perirectal abscess">perirectal abscess</span>.</p>
<p><span class="Bold">General disorders and administration site conditions:</span>  catheter site <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, general physical health deterioration, <span class="product-label-link" type="condition" conceptid="434821" conceptname="Systemic inflammatory response syndrome">systemic inflammatory response syndrome</span>.</p>
<p><span class="Bold">Hepatobiliary disorders:</span>  <span class="product-label-link" type="condition" conceptid="192956" conceptname="Cholecystitis">cholecystitis</span>.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune system disorders</span>:</span>  <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic shock</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">infestations</span>:</span>  <span class="product-label-link" type="condition" conceptid="4009031" conceptname="Abscess of toe">abscess limb</span>, <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>, <span class="product-label-link" type="condition" conceptid="433146" conceptname="Blastomycosis">blastomycosis</span>, <span class="product-label-link" type="condition" conceptid="4318388" conceptname="Injection site infection">injection site infection</span>, Klebsiella <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, <span class="product-label-link" type="condition" conceptid="28060" conceptname="Streptococcal sore throat">pharyngitis streptococcal</span>, <span class="product-label-link" type="condition" conceptid="253790" conceptname="Pneumonia due to Klebsiella pneumoniae">pneumonia Klebsiella</span>, <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, <span class="product-label-link" type="condition" conceptid="4327861" conceptname="Bacteremia due to Staphylococcus aureus">Staphylococcal bacteremia</span>, <span class="product-label-link" type="condition" conceptid="435459" conceptname="Staphylococcal infectious disease">Staphylococcal infection</span>, <span class="product-label-link" type="condition" conceptid="440653" conceptname="Toxoplasmosis">toxoplasmosis</span>.</p>
<p><span class="Bold">Metabolism and nutrition disorders:</span>  <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>.</p>
<p><span class="Bold">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">connective tissue disorders</span>:</span>  <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">bone pain aggravated</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>, <span class="product-label-link" type="condition" conceptid="24134" conceptname="Neck pain">neck pain</span>.</p>
<p><span class="Bold">Neoplasms benign, malignant and unspecified:</span>  <span class="product-label-link" type="condition" conceptid="4297353" conceptname="Leukemic infiltration of skin">leukemia cutis</span>.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span>:</span>  <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">intracranial hemorrhage</span>.</p>
<p><span class="Bold">Psychiatric disorders:</span>  <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>.</p>
<p><span class="Bold">Renal and urinary disorders:</span>  <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">loin pain</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>.</p>
<p><span class="Bold">Respiratory, thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">mediastinal disorders</span>:</span>  <span class="product-label-link" type="condition" conceptid="261687" conceptname="Hemoptysis">hemoptysis</span>, lung infiltration, <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span>, <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>.</p>
<p><span class="Bold">Skin and subcutaneous tissue disorders:</span>  <span class="product-label-link" type="condition" conceptid="133283" conceptname="Pyoderma gangrenosum">pyoderma gangrenosum</span>, <span class="product-label-link" type="condition" conceptid="135618" conceptname="Pruritic rash">rash pruritic</span>, <span class="product-label-link" type="condition" conceptid="4145436" conceptname="Induration of skin">skin induration</span>.</p>
<p><span class="Bold">Surgical and medical procedures:</span>  cholecystectomy.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular disorders</span>:</span>  <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s49"></a><a name="section-11"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">One case of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with Vidaza was reported during clinical trials.  A patient experienced <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> after receiving a single IV dose of approximately 290 mg/m<span class="Sup">2</span>, almost 4 times the recommended starting dose. The events resolved without sequelae, and the correct dose was resumed the following day. In the event of overdosage, the patient should be monitored with appropriate blood counts and should receive supportive treatment, as necessary.  There is no known specific antidote for Vidaza overdosage.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s50"></a><a name="section-12"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s51"></a><a name="section-12.1"></a><p></p>
<h2>First Treatment Cycle</h2>
<p class="First">The recommended starting dose for the first treatment cycle, for all patients regardless of baseline hematology laboratory values, is 75 mg/m<span class="Sup">2</span> subcutaneously, daily for seven days.  Patients should be premedicated for <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s52"></a><a name="section-12.2"></a><p></p>
<h2>Subsequent Treatment Cycles</h2>
<p class="First">Cycles should be repeated every four weeks.  The dose may be increased to 100 mg/m<span class="Sup">2</span> if no beneficial effect is seen after two treatment cycles and if no toxicity other than <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> has occurred. It is recommended that patients be treated for a minimum of 4 cycles. However, complete or partial response may require more than 4 treatment cycles. Treatment may be continued as long as the patient continues to benefit.</p>
<p>Patients should be monitored for hematologic response and renal toxicities (see <span class="Bold"><a href="#s13">PRECAUTIONS</a></span>), and dosage delay or reduction as described below may be necessary.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s53"></a><a name="section-12.3"></a><p></p>
<h2>Dosage Adjustment Based on Hematology Laboratory Values:</h2>
<ul class="Disc"><li>For patients with baseline (start of treatment) WBC â‰¥3.0 x10<span class="Sup">9</span>/L, ANC â‰¥1.5 x10<span class="Sup">9</span>/L, and platelets â‰¥75.0 x10<span class="Sup">9</span>/L, adjust the dose as follows, based on nadir counts for any given cycle:</li></ul>
<table rules="all">
<col align="left" width="30.533%">
<col align="left" width="23.167%">
<col align="left" width="46.300%">
<thead><tr class="First Last">
<th class="Lrule Rrule Toprule" align="center" colspan="2" valign="top">Nadir Counts</th>
<th class="Lrule Rrule Toprule" align="center" valign="top">% Dose in the Next Course</th>
</tr></thead>
<tbody><tr class="First Last">
<td class="Lrule Rrule Toprule" align="center" valign="bottom">
<span class="Underline">ANC (x10</span><span class="Sup">9</span><span class="Underline">/L)</span><br>&lt;0.5<br>0.5 â€“1.5<br>&gt;1.5</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom">
<span class="Underline">Platelets (x10</span><span class="Sup">9</span><span class="Underline">/L)<br></span>&lt;25.0<br>25.0-50.0<br>&gt;50.0</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom">50%<br>67%<br>100%</td>
</tr></tbody>
</table>
<ul class="Disc"><li>For patients whose baseline counts are WBC &lt;3.0 x10<span class="Sup">9</span>/L, ANC&lt;1.5 x10<span class="Sup">9</span>/L, or platelets &lt;75.0 x10<span class="Sup">9</span>/L, dose adjustments should be based on nadir counts and bone marrow biopsy cellularity at the time of the nadir as noted below, unless there is clear improvement in differentiation (percentage of mature granulocytes is higher and ANC is higher than at onset of that course) at the time of the next cycle, in which case the dose of the current treatment should be continued.</li></ul>
<table rules="all">
<col align="left" width="33.400%">
<col align="left" width="26.100%">
<col align="left" width="20.250%">
<col align="left" width="20.250%">
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule" align="center" rowspan="2" valign="top">WBC  or Platelet Nadir<br>% decrease in counts<br>from baseline</td>
<td class="Lrule Rrule Toprule" align="center" colspan="3" valign="top">Bone Marrow<br>Biopsy Cellularity<br>at Time of Nadir<br>(%)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center" valign="top">30-60</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">15-30</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">&lt;15</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center" rowspan="3" valign="bottom">50 â€“ 75<br>&gt; 75</td>
<td class="Lrule Rrule Toprule" align="center" colspan="3" valign="top">% Dose in the Next Course</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center" valign="top">100</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">50</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">33</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule Toprule" align="center" valign="top">75</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">50</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">33</td>
</tr>
</tbody>
</table>
<p class="First">If a nadir as defined in the table above has occurred, the next course of treatment should be given 28 days after the start of the preceding course, provided that both the WBC and the platelet counts are &gt;25% above the nadir and rising.  If a &gt;25% increase above the nadir is not seen by day 28, counts should be reassessed every 7 days.  If a 25% increase is not seen by day 42, then the patient should be treated with 50% of the scheduled dose.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s54"></a><a name="section-12.4"></a><p></p>
<p class="First"><span class="Bold">Dosage Adjustment Based on Renal Function and Serum Electrolytes:</span>  If unexplained reductions in serum <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> levels to less than 20 mEq/L occur, the dosage should be reduced by 50% on the next course.  Similarly, if unexplained elevations of BUN or serum creatinine occur, the next cycle should be delayed until values return to normal or baseline and the dose should be reduced by 50% on the next treatment course (see <span class="Bold"><a href="#s13">PRECAUTIONS</a></span> section).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s55"></a><a name="section-12.5"></a><p></p>
<p class="First"><span class="Bold">Use in Geriatric Patients:</span>  Azacitidine and its metabolites are known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>.  Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function (see <span class="Bold"><a href="#s13">PRECAUTIONS</a></span> section).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s56"></a><a name="section-12.6"></a><p></p>
<h2>Preparation of Vidaza</h2>
<p class="First">Vidaza is a cytotoxic drug and, as with other potentially toxic compounds, caution should be exercised when handling and preparing Vidaza suspensions. Please refer to <span class="Bold"><a href="#s63">Handling and Disposal</a></span> section.</p>
<p>If reconstituted Vidaza comes into contact with the skin, immediately and thoroughly wash with soap and water.  If it comes into contact with mucous membranes, flush thoroughly with water.</p>
<p>Vidaza should be reconstituted aseptically with 4 mL sterile water for injection.  The diluent should be injected slowly into the vial.  The vial should be inverted 2-3 times and gently rotated until a uniform suspension is achieved.  The suspension will be cloudy. The resulting suspension will contain azacitidine 25 mg/mL.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s57"></a><a name="section-12.6.1"></a><p></p>
<p class="First"><span class="Bold">Preparation for Immediate Administration:</span>  Doses greater than 4 mL should be divided equally into two syringes. The product may be held at room temperature for up to 1 hour, but must be administered within 1 hour after reconstitution.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s58"></a><a name="section-12.6.2"></a><p></p>
<p class="First"><span class="Bold">Preparation for Delayed Administration:</span>  The reconstituted product may be kept in the vial or drawn into a syringe.  Doses greater than 4 mL should be divided equally into two syringes. The product must be refrigerated immediately, and may be held under refrigerated conditions (2Â°C - 8Â°C, 36Â°F- 46Â°F) for up to 8 hours. After removal from refrigerated conditions, the suspension may be allowed to equilibrate to room temperature for up to 30 minutes prior to administration.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s59"></a><a name="section-12.7"></a><p></p>
<h2>Administration</h2>
<p class="First">To provide a homogeneous suspension, the contents of the syringe must be re-suspended by inverting the syringe 2-3 times and gently rolling the syringe between the palms for 30 seconds immediately prior to administration.</p>
<p>Vidaza is administered subcutaneously.  Doses greater than 4 mL should be divided equally into 2 syringes and injected into 2 separate sites. Rotate sites for each injection (thigh, abdomen, or upper arm).  New injections should be given at least one inch from an old site and never into areas where the site is tender, bruised, red, or hard.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s60"></a><a name="section-12.8"></a><p></p>
<h2>Stability</h2>
<p class="First">Reconstituted Vidaza may be stored for up to 1 hour at 25Â°C (77Â°F) or for up to 8 hours between 2 and 8Â°C (36 and 46Â°F).  The Vidaza vial is single-use and does not contain any preservatives. Unused portions of each vial should be discarded properly.  See <span class="Bold"><a href="#s63">Handling and Disposal.</a></span> Do not save any unused portions for later administration.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s61"></a><a name="section-13"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Vidaza (azacitidine for injectable suspension) is supplied as a lyophilized powder in 100 mg single-use vials packaged in cartons of 1 vial (NDC 67211-102-01).</p>
<div class="Section" data-sectionCode="44425-7">
<a name="s62"></a><a name="section-13.1"></a><p></p>
<h2>Storage</h2>
<p class="First">Store unreconstituted vials at 25Â° C (77Â° F); excursions permitted to 15Â°-30Â° C (59Â°-86Â° F) (See USP Controlled Room Temperature).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s63"></a><a name="section-13.2"></a><p></p>
<h2>Handling and Disposal</h2>
<p class="First">Procedures for proper handling and disposal of anticancer drugs should be applied. Several guidelines on this subject have been published<span class="Sup">1-8</span>. There is no general agreement that all of the procedures recommended in the guidelines are necessary or appropriate.</p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="s64"></a><a name="section-14"></a><p></p>
<h1>REFERENCES</h1>
<ol class="Arabic">
<li> ONS Clinical Practice Committee. Cancer Chemotherapy Guidelines and Recommendations for Practice. Pittsburgh, Pa: Oncology Nursing Society; 1999:32-41.</li>
<li> Recommendations for the safe handling of parenteral antineoplastic drugs. Washington, DC: Division of Safety, National Institutes of Health; 1983. US Dept of Health and Human Services, Public Health Service publication NIH 83-2621.</li>
<li> AMA Council on Scientific Affairs. Guidelines for handling parenteral antineoplastics. <span class="Italics">JAMA</span>. 1985;253:1590-1592.</li>
<li> National Study Commission on Cytotoxic Exposure. Recommendations for handling cytotoxic agents. 1987. Available from Louis P. Jeffrey, Chairman, National Study Commission on Cytotoxic Exposure. Massachusetts College of Pharmacy and Allied Health Sciences, 179 Longwood Avenue, Boston, MA 02115.</li>
<li> Clinical Oncological Society of Australia. Guidelines and recommendations for safe handling of antineoplastic agents. <span class="Italics">Med J Australia</span>. 1983;1:426-428.</li>
<li> Jones RB, Frank R, <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">Mass</span> T. Safe handling of chemotherapeutic agents: a report from the Mount Sinai Medical Center. <span class="Italics">CA-A Cancer J for Clin.</span> 1983;33:258-263.</li>
<li> American Society of Hospital Pharmacists. ASHP technical assistance bulletin on handling cytotoxic and hazardous drugs. <span class="Italics">Am J Hosp Pharm.</span> 1990;47:1033-1049.</li>
<li> Controlling Occupational Exposure to Hazardous Drugs. (OSHA Work-Practice Guidelines). <span class="Italics">Am J Health-Syst Pharm.</span> 1996;53:1669-1685.</li>
</ol>
<p class="First">Manufactured for: Pharmion Corporation</p>
<p>Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Boulder, CO 80301</p>
<p>Manufactured by: Ben Venue Laboratories, Inc.</p>
<p>Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Bedford, OH 44146</p>
<p><span class="Bold">Edition Date: August 31, 2004<br>VID-P01</span></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>VIDAZAÂ 		
					</strong><br><span class="contentTableReg">azacitidine injection, powder, lyophilized, for suspension</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:67211-102</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">SUBCUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>azacitidine</strong> (azacitidine) </td>
<td class="formItem"></td>
<td class="formItem">100Â mg Â inÂ 4Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>mannitol</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:67211-102-01</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">4 mL in 1 VIAL, SINGLE-USE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Pharmion Corporation</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 12/2006<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>0C0C40D5-1994-E8BA-C648-0F4A1BB5A2BE</div>
<div>Set id: e437efe0-9c6a-4f87-b3b4-de90443b095f</div>
<div>Version: 2</div>
<div>Effective Time: 20061222</div>
</div>
</div>Â <div class="DistributorName">Pharmion Corporation</div></p>
</body></html>
